Vertex Pharmaceuticals (NASDAQ:VRTX) Releases Quarterly Earnings Results, Beats Expectations By $0.23 EPS

Vertex Pharmaceuticals (NASDAQ:VRTX) issued its quarterly earnings results on Monday. The pharmaceutical company reported $4.47 EPS for the quarter, topping the consensus estimate of $4.24 by $0.23, FiscalAI reports. The company had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $2.99 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. Vertex Pharmaceuticals’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.06 EPS.

Here are the key takeaways from Vertex Pharmaceuticals’ conference call:

• Vertex reported strong Q1 results with $2.99 billion in product revenue (+8% YoY), reiterated full?year guidance of $12.95–13.1 billion, ended Q1 with ~$13 billion in cash, and continued share repurchases — supporting near?term financial momentum.
• Pivotal RAINIER interim Phase III data for povetacicept (Povi) in IgAN were described as “sparkling” — a 52% proteinuria reduction vs baseline (?49.8% vs placebo), favorable safety, a 27?day BLA filing turnaround, and initiation/advancement of PMN and gMG programs, underpinning a new renal franchise opportunity.
• Commercial momentum outside CF: CASGEVY has >500 patients initiated and delivered $43M in Q1 while securing reimbursement progress (e.g., Germany), and JOURNAVX surpassed 1M prescriptions written with 350k scripts in Q1 and expanded payer coverage (?240M lives), supporting the company’s goal of >$500M non?CF revenue in 2026.
• CF franchise remains core: ALYFTREK exceeded $1 billion cumulative revenue and recent label expansions for ALYFTREK/TRIKAFTA extend eligibility to ~95% of people with CF; next?gen modulators (VX?828, VX?581, VX?272) are progressing with a VX?828 patient readout expected H2 2026.
• Vertex discontinued the VX?522 mRNA program for patients who produce no CFTR protein due to lung inflammatory/tolerability issues, meaning the company will not advance this delivery approach for the hardest?to?treat CF patients and must pursue alternative modalities.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $429.85 on Tuesday. Vertex Pharmaceuticals has a twelve month low of $362.50 and a twelve month high of $507.92. The firm’s 50 day moving average price is $453.82 and its two-hundred day moving average price is $449.48. The firm has a market cap of $109.34 billion, a P/E ratio of 28.04, a PEG ratio of 1.84 and a beta of 0.30.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Q1 adjusted EPS beat expectations ($4.47 vs. ~$4.24) and net margin/ROE remained strong; management reiterated full?year revenue guidance near the street (~$13.0B). Business Wire: Q1 Results
• Positive Sentiment: Sales growth was driven by new disease?area franchises — management said KASJEVY and GERNAVICS (and other recent launches) accounted for a sizeable portion of product growth, signaling diversification beyond cystic fibrosis. Fool: Earnings Call Highlights
• Positive Sentiment: Regulatory progress continues to expand the CF franchise (FDA expanded ALYFTREK to younger patients), supporting the durable cash flow base that funds R&D and launches. Yahoo: FDA ALYFTREK Expansion
• Neutral Sentiment: Company hosted an earnings call / transcript is available — useful for investors wanting management detail on product uptake, pipeline timing and guidance assumptions. Seeking Alpha: Call Transcript
• Neutral Sentiment: Street reaction is mixed but not overwhelming; company kept FY outlook essentially unchanged (guidance ~ $13.0–13.1B), which many view as confirmation rather than an upgrade. Yahoo: Sales Beat / Guidance
• Negative Sentiment: Market reaction turned negative after some outlets flagged mixed details: third?party data noted revenue/EPS discrepancies vs. certain estimates, operating cash flow fell and capex rose sharply, and notable insider sales were highlighted — these factors pressured the stock. QuiverQuant: Stock Falls on Q1
• Negative Sentiment: Some headlines described the report as “mixed” (revenue roughly in?line but not a clear beat in all feeds), which can trigger short?term selling even with solid fundamentals. Yahoo: Vertex Dips on Mixed Report

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Duncan Mckechnie sold 4,910 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $487.65, for a total value of $2,394,361.50. Following the transaction, the executive vice president owned 17,559 shares of the company’s stock, valued at approximately $8,562,646.35. The trade was a 21.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Amit Sachdev sold 58,613 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $468.83, for a total transaction of $27,479,532.79. Following the completion of the transaction, the executive vice president directly owned 58,934 shares in the company, valued at approximately $27,630,027.22. The trade was a 49.86% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 80,431 shares of company stock valued at $37,875,167. 0.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of VRTX. Arrowstreet Capital Limited Partnership lifted its stake in Vertex Pharmaceuticals by 520.1% in the third quarter. Arrowstreet Capital Limited Partnership now owns 381,195 shares of the pharmaceutical company’s stock valued at $149,291,000 after buying an additional 319,725 shares in the last quarter. Man Group plc lifted its stake in Vertex Pharmaceuticals by 184.3% in the third quarter. Man Group plc now owns 362,774 shares of the pharmaceutical company’s stock valued at $142,077,000 after buying an additional 235,156 shares in the last quarter. Alyeska Investment Group L.P. lifted its stake in Vertex Pharmaceuticals by 311.0% in the third quarter. Alyeska Investment Group L.P. now owns 267,169 shares of the pharmaceutical company’s stock valued at $104,634,000 after buying an additional 202,169 shares in the last quarter. Amundi lifted its stake in Vertex Pharmaceuticals by 16.6% in the fourth quarter. Amundi now owns 1,304,161 shares of the pharmaceutical company’s stock valued at $591,254,000 after buying an additional 185,190 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Vertex Pharmaceuticals by 20.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 945,660 shares of the pharmaceutical company’s stock valued at $428,726,000 after buying an additional 162,074 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Analysts Set New Price Targets

VRTX has been the subject of a number of analyst reports. Wolfe Research upgraded shares of Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 price objective for the company in a report on Tuesday, January 6th. Stifel Nicolaus boosted their price objective on shares of Vertex Pharmaceuticals from $445.00 to $466.00 and gave the company a “hold” rating in a report on Friday, February 13th. Truist Financial upgraded shares of Vertex Pharmaceuticals to a “strong-buy” rating in a report on Monday, April 27th. Sanford C. Bernstein restated an “outperform” rating and set a $577.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Finally, Wall Street Zen cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $554.83.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.